Wegovy

A large analysis of previous studies has found that patients who stop taking weight loss medications will see the beneficial effects disappear within two years, causing weight and health issues to reappear.  Researchers reviewed data on 9,341 obese or overweight patients treated across 37 studies with 18 different weight-loss medications, finding that they gained approximately…

GLP-1 drugs have become the hottest drug class in a generation, driven by an obesity epidemic affecting 40% of American adults and linked to diabetes, heart disease and a growing list of other conditions. But there’s a catch: up to two-thirds of adults report some level of needle fear. A 2022 PLOS One international survey…

The FDA’s Dec. 30 approval of Vanda Pharmaceuticals’ Nereus (tradipitant) adds a rare new option to a category that has leaned for decades on older anticholinergics and antihistamines, including the scopolamine patch and over-the-counter products such as meclizine and dimenhydrinate. In reporting on the decision, Reuters noted the approval as the first new FDA-cleared treatment…

Novo Nordisk, which helped kickstart the GLP-1 craze by expanding a diabetes drug to obesity, is slimming down the prices of Ozempic and Wegovy. That won’t necessarily translate into steep revenue drops in 2026 though. Current projections still point to rising semaglutide sales next year, and a drop in price could lead to a boost…

Pfizer has filed two lawsuits against the metabolic-focused startup Metsera and Novo Nordisk as of Tuesday. The first suit, filed last Friday, claims that Novo Nordisk’s rival bid for Metsera is a move “to suppress competition,” Pfizer said in a press release.  Metsera could be a vital acquisition for either company. The company is developing…

Once so valuable its market capitalization eclipsed that of its home country of Denmark, pharmaceutical giant Novo Nordisk is now showing signs of strain. Most recently, several members of Novo Nordisk’s board of directors quit after failing to reach an agreement with the Novo Nordisk Foundation, the firm’s controlling shareholder (via Novo Holdings), on the…

It took just one off-hand comment during a White House event about fertility treatments for President Trump to temporarily wipe tens of billions from the market cap of the world’s leading obesity drugmakers. Trump’s vow Thursday to bring Ozempic down to $150 per month, calling it “the fat-loss drug,” sent Novo Nordisk shares down 6.3%…

Novo Nordisk’s $5.2 billion acquisition of Akero Therapeutics sits at the center of 2025’s hottest M&A space: MASH/metabolic disease. The deal, announced October 9, represents the largest of three major Fibroblast Growth Factor 21 (FGF21) analog acquisitions in five months. Across the broader landscape, 2025 pharma M&A activity reached approximately $70 billion in upfront consideration…

Novo Nordisk has laid off dozens of employees at its plant in North Carolina, an analysis of LinkedIn posts by Reuters found. The layoffs come after the company announced a plan to cut 9,000 jobs globally in an effort to compete with Eli Lilly last month. The exact number of layoffs at the Clayton plant…

Novo Nordisk, the manufacturer of Ozempic, announced a plan to reduce its global workforce by approximately 9,000 positions today. Around 5,000 positions are expected to be cut in Denmark. This will reduce the company’s workforce from its current 78,400 positions to approximately 69,400.  The company’s stock has fallen about 58% over the past year as…

An original investigation published in JAMA Ophthalmology indicated that the megablockbuster metabolic medication Wegovy (semaglutide) may increase the risk of a serious eye condition. The research, published on Wednesday, examined the occurrence of nonarteritic anterior ischemic optic neuropathy (NAION) in patients taking semaglutide. The GLP-1 receptor agonists Wegovy, Ozempic, and Rybelsus, all containing the active…

The recent FDA approval of a cardiovascular risk reduction indication for Wegovy (semaglutide) could point toward a significant opportunity for pharma companies seeking to reshape payer perceptions and expand coverage for next-gen metabolic therapies. This regulatory shift, allowing Wegovy to be prescribed for reducing the risk of major adverse cardiovascular events such as heart attack…

Semaglutide was already one of the best-selling drugs of recent memory. And Novo Nordisk the fastest-growing Big Pharma firm. Now, the FDA’s decision to expand the label of its weight-loss version of the drug to include cardiovascular benefits could help unlock more growth momentum for Novo Nordisk. This positions Wegovy as the first weight-loss medication…

No longer just a diabetes company, Novo Nordisk’s semaglutide-based therapies have fueled its rise to pharma powerhouse status. From 2021 to 2023, the company cemented its position as the fastest-growing Big Pharma player, reaching a 35% year-over-year growth rate in 2023 and 74% growth from 2020 to 2023 when measured in U.S. dollars. While Pfizer…

The GLP-1 drug market continues to boom lately thanks to highly effective new medications like Novo Nordisk’s Wegovy and continued demand for the drug class in diabetes. The runaway success of Wegovy and Ozempic (both formulations of semaglutide) has caused Novo Nordisk’s share price to skyrocket in 2023, briefly making the Danish pharmaceutical company the most…

Novo Nordisk (NYSE:NVO) continues to face supply shortages for its Wegovy (semaglutide) pens, which are FDA approved for weight management.  Against that backdrop, a growing number of companies have begun selling compounded versions of the drug.  Drug compounding involves “combining, mixing, or altering ingredients to create a medication tailored to the needs of an individual patient,”…